According to a recent survey, colon cancer is one of the most common types of cancer worldwide. It occurs when abnormal cells grow in the lining of the colon or rectum and can spread to other parts of the body if left untreated. Colon cancer typically develops over several years, often without any symptoms in its early stages. However, as it progresses, patients may experience abdominal pain, changes in bowel habits, blood in their stool or rectal bleeding. Risk factors for developing colon cancer include age, family history of the disease, inflammatory bowel disease and poor diet choices such as high-fat foods and low fiber intake. Thankfully, if detected early through routine screenings like a colonoscopy or fecal occult blood test (FOBT), there are effective treatment options available such as surgery chemotherapy and radiation therapy that can help improve survival rates for those diagnosed with this type of cancer.
1.
Examines Office-Based Transperineal Prostate Biopsies Methodology.
2.
Patients value communication skills from cancer surgeons across six key areas, according to research
3.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
4.
Underprescribed for Alcohol Use Disorder is pharmacotherapy.
5.
A new mechanism of radioresistance formation demonstrated in lung adenocarcinoma
1.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
2.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
3.
Iron Deficiency Anemia: Challenges in Diagnosis and Treatment
4.
Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers
5.
The Potential of Amifostine in Cancer Treatment: A Revolutionary Breakthrough
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
3.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
4.
Updates on the First Line Management of ALK+ NSCLC
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation